Feb 27, 2016

Meet&Greet with Carlos Sainz in Barcelona in support of Wings for Life

All proceeds will go to Red Bull’s non-profit foundation and help fund medical research

Carlos Sainz will take part in a unique and benefic experience for fans of Formula One in support of Wings For Life, an international non-profit spinal cord research foundation founded by Red Bull.

On the upcoming March 3rd, the Scuderia Toro Rosso driver will hold a Meet&Greet at Circuit de Barcelona-Catalunya. It will be a unique opportunity for his fans to meet him in person, take a photo with him and even ask for an autograph before he embarks in what will be his second season in Formula One.

The event includes a tour around the most restricted areas of the Circuit, such as the briefing room, the podium or the paddock and a lap around the service road around the track while teams resume their winter testing. Fans will also attend a conference about Formula One by journalist Josep Lluís Merlos before meeting Carlos at 11:30 am.

Carlos encourages all his fans to attend the event: "Any charity action is worth the effort and in this case the Red Bull's Wings for Life foundation works hard each day in his pursuit for finding a cure for spinal cold injuries. It is a fantastic project with still a lot of work to be done and this is why I think we can help them. Don't miss it, we'll meet at the track on March 3rd".

To take part in this event, it is necessary to buy tickets at the Circuit de Barcelona-Catalunya website, the organizer ((enlace a https://proticketing.com/circuitcat/es_ES/entradas/evento/4774/session/264022/select). Seating is limited and each ticket costs 100 euros that will contribute in its totality to medical research.

About Wings for Life
Wings for Life is an international non-profit spinal cord research foundation founded by Red Bull. It funds world-class scientific research and clinical trials around the globe. Advancement in spinal cord research is largely base don private initiatives and public donations, as it is not considered a widespread condition and therefore government support or funding from pharmaceutical companies is limited.